Amgen's (NASDAQ:AMGN) Aimovig (erenumab) demonstrated a significant treatment effect in a Phase 3b clinical trial called LIBERTY in patients who had failed two-to-four preventative treatments. The results were presented at the Annual Meeting of the American Academy of Neurology in Los Angeles.
Over a 12-week treatment period, 30.3% of patients receiving monthly subcutaneous injections of Aimovig experienced at least a 50% reduction in migraine days compared to 13.7% for placebo (p<0.002).
The company's U.S. marketing application is currently under FDA review with an action date of May 17.
Previously: Amgen's Aimovig successful in late-stage study in treatment-resistant migraine (Jan. 22)
Now read: Evelo Biosciences Files For U.S. IPO »
Subscribe for full text news in your inbox